You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CARGLUMIC ACID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Carglumic Acid, and when can generic versions of Carglumic Acid launch?

Carglumic Acid is a drug marketed by Navinta Llc and Novitium Pharma and is included in two NDAs.

The generic ingredient in CARGLUMIC ACID is carglumic acid. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carglumic acid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Carglumic Acid

A generic version of CARGLUMIC ACID was approved as carglumic acid by NOVITIUM PHARMA on October 13th, 2021.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CARGLUMIC ACID?
  • What are the global sales for CARGLUMIC ACID?
  • What is Average Wholesale Price for CARGLUMIC ACID?
Drug patent expirations by year for CARGLUMIC ACID
Drug Prices for CARGLUMIC ACID

See drug prices for CARGLUMIC ACID

Recent Clinical Trials for CARGLUMIC ACID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Taiwan University HospitalN/A
King Abdullah International Medical Research CenterPhase 3
University Hospitals Cleveland Medical CenterPhase 2

See all CARGLUMIC ACID clinical trials

Pharmacology for CARGLUMIC ACID

US Patents and Regulatory Information for CARGLUMIC ACID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Navinta Llc CARGLUMIC ACID carglumic acid TABLET, FOR SUSPENSION;ORAL 213395-001 Jun 22, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novitium Pharma CARGLUMIC ACID carglumic acid TABLET, FOR SUSPENSION;ORAL 213729-001 Oct 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CARGLUMIC ACID

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Eurocept International BV Ucedane carglumic acid EMEA/H/C/004019
Ucedane is indicated in treatment of:hyperammonaemia due to N-acetylglutamate synthase primary deficiency;Hyperammonaemia due to isovaleric acidaemia;Hyperammonaemia due to methymalonic acidaemia;Hyperammonaemia due to propionic acidaemia.
Authorised yes no no 2017-06-23
Recordati Rare Diseases Carbaglu carglumic acid EMEA/H/C/000461
Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.
Authorised no no no 2003-01-24
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.